Skip to content
Study details
Enrolling now

A Study of Suvorexant for Insomnia in People with Opioid Use Disorder

Merck Sharp & Dohme LLC
NCT IDNCT06655883ClinicalTrials.gov data as of Apr 2026
Phase

Phase 3

Target enrollment

300

Study length

about 1.7 years

Ages

18–70

Locations

10 sites in CT, GA, MD +6

What this study is about

This trial is testing if suvorexant, a medication, helps people with opioid use disorder (OUD) sleep better. Researchers are also looking at how safe and well-tolerated suvorexant is compared to a placebo.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take Placebo
  • 2.Take Suvorexant

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Oral

How treatment is administered

Treatment Assignment
Randomized & Blinded

You may get a placebo/standard care, and you won't know which.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

suvorexant

Drug routes

oral (Oral Tablet)

Endpoints

Primary: Change from Baseline in Total Sleep Time at Week 8, Number of Participants Who Discontinue Study Treatment Due to an AE, Number of Participants Who Experience One or More Adverse Events (AEs), Number of Participants Who Experience One or More Serious Adverse Events (SAEs)

Secondary: Change from Baseline in Wakefulness after Persistent Sleep Onset at Week 8